Table 5.
Profile of toxicities during NAC and IMRT between two groups.
| Adverse events | During NAC | During IMRT | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NAC + CCRT | NAC + IMRT | P | NAC + CCRT | NAC + IMRTcancer incidence, mortalitycancer incidence, mortality | P | ||||||
| 0–2 | 3–4 | 0–2 | 3–4 | 0–2 | 3–4 | 0–2 | 3–4 | ||||
| Haematologic | |||||||||||
| Leukopenia | 204 | 83 | 183 | 105 | 0.066 | 221 | 67 | 248 | 40 | 0.005 | |
| Neutropenia | 183 | 105 | 181 | 107 | 0.931 | 229 | 59 | 249 | 39 | 0.035 | |
| Anaemia | 281 | 7 | 280 | 8 | 1.000 | 279 | 9 | 285 | 3 | 0.145 | |
| Thrombocytopenia | 281 | 7 | 282 | 6 | 1.000 | 281 | 7 | 286 | 2 | 0.179 | |
| Liver function | 287 | 1 | 286 | 2 | 1.000 | 288 | 0 | 288 | 0 | 1.000 | |
| Renal function | 287 | 1 | 288 | 0 | 1.000 | 288 | 0 | 288 | 0 | 1.000 | |
| Non-haematologic | |||||||||||
| Mucositis | 286 | 2 | 285 | 3 | 1.000 | 212 | 76 | 248 | 40 | <0.0001 | |
| Dermatitis | 287 | 1 | 288 | 0 | 1.000 | 281 | 7 | 283 | 5 | 0.770 | |
| Diarrhoea | 282 | 6 | 284 | 4 | 0.750 | 288 | 0 | 288 | 0 | 1.000 | |
| Nausea/vomiting | 267 | 21 | 272 | 16 | 0.497 | 243 | 45 | 281 | 7 | <0.0001 | |
Abbreviations: NAC neoadjuvant chemotherapy; IMRT intensity-modulated radiotherapy; CCRT concurrent chemoradiotherapy.